Relationship Between Heart Failure With Preserved Ejection Fraction and Nonalcoholic Fatty Liver Disease.

April 7, 2023 updated by: Asmaa Elsayed Khalifa, Sohag University
The aim of our study to determine the demography, relation between patients with heart failure with preserved ejection fraction and those with nonalcoholic fatty liver disease in Sohag university hospital.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

type of the study cross sectional study to study the relationship between heart failure with preserved ejection fraction and nonalcoholic fatty liver disease.

Study Type

Observational

Enrollment (Anticipated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Usama A Arafa, professor
  • Phone Number: 01063064007

Study Locations

  • Egypt
      • Sohag, Egypt, 82515
        • Asmaa E khalifa
        • Contact:
        • Contact:
          • Usama A Arafa, prof
          • Phone Number: 01063064007
    • El Monshah
      • Sohag, El Monshah, Egypt, 82515
        • Asmaa elsayed khalifa
        • Contact:
        • Contact:
          • Usama A Arafa, professor
          • Phone Number: 01063064007

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

all patients presented by heart failure with preserved ejection fraction and those with fatty liver disease

Description

Inclusion Criteria: clinical diagnosis of heart failure with preserved ejection fraction.

clinical diagnosis of nonalcoholic fatty liver disease. -

Exclusion Criteria: rheumatic heart disease ,congenital heart disease , ischemic heart disease ,heart failure with reduced ejection fraction , hepatitis B virus , hepatitis C virus .

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
HFpEF(heart failure with preserved ejection fraction)
chronic heart failure with echocardiographic finding of LVEF (left ventricular ejection fraction) equal or more than 50% , diagnostic test :Abdominal ultrasound and transient elastography for detecting non alcoholic fatty liver disease .
Other: echocardiography
to determine finding of heart failure with preserved ejection fraction and non alcoholic fatty liver disease
Other Names:
  • abdominal ultrasound and transient elastography
NAFLD(non alcoholic fatty liver disease)
ultrasound and transient elastographic finding of fatty liver disease, diagnostic test :echocardiography to determine heart failure with preserved ejection fraction .
Other: echocardiography
to determine finding of heart failure with preserved ejection fraction and non alcoholic fatty liver disease
Other Names:
  • abdominal ultrasound and transient elastography

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
collection of results of echocardiography (those detect HFpEF) with abdominal ultrasound and transient elastography results (those detect NAFLD) and find relationship between the results.
Time Frame: up to 28 weeks.
looking for relationship between echocardiographic findings (that detect heart failure with preserved ejection fraction) and finding in abdominal ultrasound and transient elastography (detection of nonalcoholic fatty liver disease) to detect the relationship between those two diseases.
up to 28 weeks.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sohag University

Investigators

  • Study Chair: Aml K Ahmed, A professor, Sohag university Hospital
  • Study Chair: Alshimaa L Hamed, lecturer, Sohag university Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

April 29, 2023

Primary Completion (Anticipated)

July 1, 2023

Study Completion (Anticipated)

August 30, 2023

Study Registration Dates

First Submitted

March 26, 2023

First Submitted That Met QC Criteria

April 7, 2023

First Posted (Actual)

April 21, 2023

Study Record Updates

Last Update Posted (Actual)

April 21, 2023

Last Update Submitted That Met QC Criteria

April 7, 2023

Last Verified

April 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Soh-Med-23-02-03

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Heart Failure With Preserved Ejection Fraction

Clinical Trials on echocardiography

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe